The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Proarrhythmia in Patients Treated for Atrial Fibrillation or Flutter
Abstract
OBJECTIVE: To review data on the type, mechanism, and prevalence of the proarrhythmic effect of drugs used to treat atrial fibrillation or flutter. DATA SOURCES: English-language literature from the early 1960s to the present was identified by manual search of the literature; relevant articles were reviewed. Pertinent earlier studies were identified from references in the articles reviewed and were included when relevant. STUDY SELECTION: All studies, controlled and uncontrolled, as well as individual case reports that contained data convincingly linking atrial antiarrhythmic therapy to a proarrhythmic side effect were included. DATA EXTRACTION: Key data were extracted from each article in studies in which a causal relationship between the use of a drug and a proarrhythmic response appeared likely. DATA SYNTHESIS: Antiarrhythmic therapy aimed at stabilizing the atrium may have adverse effects on the ventricle including torsade de pointes and, less commonly, sustained ventricular tachycardia. Different antiarrhythmic agents appear to have differing potentials for this proarrhythmic response, which is most common with class 1A agents. Other proarrhythmic responses to atrial antiarrhythmic agents include the acceleration of the ventricular response either by enhancing atrioventricular nodal or bypass tract conduction or by converting atrial fibrillation to flutter with 1:1 conduction. Calcium-channel blocking agents and, less commonly, digoxin may perpetuate the duration of paroxysmal atrial fibrillation, and virtually all agents can cause sinus node dysfunction or atrioventricular block. CONCLUSIONS: Although drug therapy for atrial fibrillation or flutter is generally well tolerated, the potential exists for uncommon but serious proarrhythmic effects. Knowledge of the risk factors and symptoms of these adverse reactions will help to further reduce this risk.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ventricular fibrillation in the Wolff-Parkinson-White syndrome
Klein, G. J., Bashore, T. M., Sellers, T. D., Pritchett, E. L. C., Smith, W. M., & Gallagher, J. J. (1979) · New England Journal of Medicine · doi:10.1056/nejm197911153012003 · Cited by 830
The long QT syndromes: A critical review, new clinical observations and a unifying hypothesis
Jackman, W. M., Friday, K. J., Anderson, J. L., Aliot, E. M., Clark, M., & Lazzara, R. (1988) · Progress in Cardiovascular Diseases · doi:10.1016/0033-0620(88)90014-x · Cited by 783
A new approach to the differential diagnosis of a regular tachycardia with a wide QRS complex
Brugada, P., Brugada, J., Mont, L., Smeets, J., & Andries, E. W. (1991) · Circulation · doi:10.1161/01.cir.83.5.1649 · Cited by 738 · cited 1×
“Newly defined criteria for distinguishing ventricular tachycardia from aberrant conduction may be helpful in determining the origin of a wide-complex tachycardia (104), but these criteria may not be as sensitive and specific in drug-induced aberration compared with aberrant conduction in the drug-free state (80, 104,…”
BackgroundSupraventricular tachycardia mimicking ventricular tachycardia during flecainide treatment
Crijns, H. J., van Gelder, I. C., & Lie, K. I. (1988) · The American Journal of Cardiology · doi:10.1016/0002-9149(88)90282-2 · Cited by 120
Atrial flutter in patients treated for atrial fibrillation with propafenone
Murdock, C. J., Kyles, A. E., Yeung-Lai-Wah, J. A., Qi, A., Vorderbrugge, S., & Kerr, C. R. (1990) · The American Journal of Cardiology · doi:10.1016/0002-9149(90)91144-u · Cited by 114 · cited 3×
“Murdock and colleagues (52) noted the occurrence of atrial flutter in 14 of 82 patients treated with propafenone for atrial fibrillation, three of whom developed 1:1 AV conduction with ventricular rates of 200 to 275 beats per minute and QRS widths of up to 160 ms.”
Background
Cited by
Falk, R. H. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441407 · Cited by 428
Self-citationGuidelines for Pharmacotherapy of Atrial Fibrillation (JCS 2013): – Digest Version –
JCS Joint Working Group (2014) · Circulation Journal · doi:10.1253/circj.cj-66-0092 · Cited by 427
Wolf, R. K., Schneeberger, E. W., Osterday, R., Miller, D., Merrill, W., Flege, J. B., & Gillinov, A. M. (2005) · The Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2005.03.041 · Cited by 392
MEREGALLI, P., WILDE, A., & TAN, H. (2005) · Cardiovascular Research · doi:10.1016/j.cardiores.2005.03.005 · Cited by 374
Narrow therapeutic index drugs: a clinical pharmacological consideration to flecainide
Tamargo, J., Le Heuzey, J.-Y., & Mabo, P. (2015) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-015-1832-0 · Cited by 276
Metadata
- Authors
- Falk, R. H.
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 1992-07-15
- Volume
- 117
- Issue
- 2
- Pages
- 141-150
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2079431413
- Cited by
- 185
- References
- 5
- FWCI
- 3.73
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Proarrhythmia in Patients Treated for Atrial Fibrillation or Flutter. https://app.cochat.ai/papers/10.7326/0003-4819-117-2-141
- The paper
- Falk, R. H. (1992). Proarrhythmia in Patients Treated for Atrial Fibrillation or Flutter. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-117-2-141
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.